If You Invested in Elite Pharmaceuticals Inc (ELTP)

Elite Pharmaceuticals, Inc. (ELTP) is a specialty pharmaceutical company focused on the development, manufacture, and distribution of niche generic drug products. According to company disclosures and SEC filings, Elite operates in the pharmaceutical preparation manufacturing industry within the broader manufacturing sector and trades its common stock on the OTCQB market under the symbol ELTP.

Elite states that its business centers on niche generic products, with an emphasis on oral, solid dose formulations. The company’s product lines include immediate-release and controlled-release solid oral dose products. These products are marketed under the Elite Laboratories, Inc. label and also through licenses granted to third-party pharmaceutical marketing and distribution organizations, including TAGI Pharma as noted in company press releases. This combination of owned-label distribution and licensing arrangements forms a key part of Elite’s commercial approach.

Elite reports that it operates a cGMP and DEA-registered research, development, and manufacturing facility located in Northvale, New Jersey. The company has also disclosed the expansion of its campus in Northvale, including a new FDA-approved facility with packaging, inventory, and warehouse space and a packaging line designed to increase production capacity. This infrastructure supports Elite’s ability to develop, manufacture, package, and distribute its generic pharmaceutical products.

Business focus and product profile

Company press releases describe Elite as being engaged in the development, manufacture, and distribution of niche generic products. Elite highlights a focus on oral, controlled-release drug products, while also offering immediate-release solid oral dose products. The company has disclosed multiple generic product launches and approvals, including:

• Lisdexamfetamine products, which Elite identifies as a significant contributor to revenue and operating income growth in several reported periods.
• A generic version of Requip XL (Ropinirole Extended-Release Tablets USP), with strengths of 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg, to be marketed and sold under the Elite Laboratories label.
• A generic version of Percocet (oxycodone hydrochloride and acetaminophen tablets, USP CII) in multiple strengths, indicated for the relief of moderate to moderately severe pain, as described in Elite’s press communications.

Elite has also reported positive results from a pivotal bioequivalence study for an undisclosed anticoagulant generic drug product. The company states that it is compiling data to file an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for this product, and notes that commercialization will depend on successful filing, FDA approval, and addressing an unexpired patent listed in the FDA’s Orange Book.

Regulatory environment and facilities

Elite’s operations, as described in its news releases and SEC filings, are subject to FDA oversight and DEA regulations. The company emphasizes that its facilities are cGMP-compliant and DEA-registered, which is central to its ability to handle controlled substances and manufacture regulated pharmaceutical products. The new FDA-approved expanded campus in Northvale, New Jersey, includes a packaging line that the company reports is capable of producing a high volume of bottles per minute. Elite has indicated that this expansion allows it to convert existing packaging space into additional manufacturing suites and significantly increase production capacity.

Corporate communications and reporting

Elite Pharmaceuticals regularly communicates financial and operational updates through press releases and SEC filings, including Forms 10-K, 10-Q, and 8-K. The company has reported financial results for its fiscal year and subsequent quarters, attributing notable increases in revenues and operating income to sales of its lisdexamfetamine products and growth in Elite label product lines. Elite also frequently announces conference calls to discuss financial results and provide general business updates, inviting stockholders to submit questions in advance.

In SEC Form 8-K filings, Elite identifies itself as a Nevada corporation with principal executive offices in Northvale, New Jersey, and lists its common stock, par value $0.001 per share, as trading under the symbol ELTP on the OTCQB. These filings also reference press releases regarding FDA approvals, financial results, and conference call logistics.

Role within the generic pharmaceutical space

Based on the company’s own descriptions, Elite positions itself within the niche generic segment of the pharmaceutical market. Rather than presenting itself as a broad-based pharmaceutical conglomerate, Elite emphasizes specific generic products and controlled-release oral formulations. The company’s disclosures highlight activities such as:

• Developing and manufacturing generic equivalents of branded drugs, including controlled substances and extended-release formulations.
• Conducting bioequivalence studies to support ANDA filings with the FDA.
• Using a combination of Elite-branded distribution under the Elite Laboratories label and licensing arrangements with other pharmaceutical marketing and distribution organizations.

Elite’s communications reference market data from IQVIA for certain branded products and their generic equivalents, indicating the scale of the reference markets for some of the products it targets. These references are used by the company to provide context for the potential of its generic offerings.

Stock information and trading venue

According to Elite’s SEC filings, the company’s common stock trades on the OTCQB market under the ticker symbol ELTP. The filings identify Elite Pharmaceuticals, Inc. as incorporated in Nevada, with an SEC Commission File Number of 001-15697 and an IRS Employer Identification Number disclosed in the filings. The company uses periodic and current reports to provide investors with information on financial results, regulatory developments, and material events.

FAQs about Elite Pharmaceuticals, Inc. (ELTP)